ClinicalTrials.gg
Not yet recruitingNCT06413134Updated Nov 19, 2026

KPAP Adherence Crossover Study

An interventional study of KPAP and APAP in Obstructive Sleep Apnea, sponsored by SleepRes Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by SleepRes Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 755 studies in Sleep Apnea, Obstructive with a site in United States — 127 open to participants now, 162 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.

Planned enrollment
390th of 596
30 · median 49
Started
2027
with 1 other
No phase
412 of 755
68 open now
Primary completion
2027-12
later than 114 of 161 live
Registered
664th of 755
by date

Among the 755 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 390th largest by planned enrollment of the 596 interventional ones that give a count, is one of 2 that started in 2027, is one of 412 with no phase, reaches primary completion later than 114 of the 161 other live ones, and was the 664th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

127 of the 755 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:

122 more — sign in →

All 127 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 755 studies in Sleep Apnea, Obstructive with a site in United States, or all of them as a file.
02

Study summary

A device able to provide less positive airway pressure (PAP) for the entire duration of inspiration and roughly half the duration of expiration, designated KPAP, is being developed by SleepRes for the treatment of obstructive sleep apnea (OSA). In prior studies, the administration of higher inspiratory than expiratory PAP did not substantially increase treatment efficacy or adherence to continuous PAP (CPAP), which remains low. In our recent investigation, we demonstrated that the addition of a resistor to the CPAP circuit to reduce inspiratory PAP increased subjective comfort. In another study, we showed that KPAP improved subjective comfort during wakefulness vs. fixed CPAP, while maintaining treatment efficacy. The present study, KPAP Adherence 1, is a randomized, crossover study designed to examine whether KPAP can improve adherence over APAP as an at home treatment for OSA.

Read the detailed description

The KPAP Adherence 1 is a randomized, crossover study in which the adherence to therapy will be compared between KPAP and standard APAP. Participants will be chosen from a pool of patients who are PAP-naïve and who have received either a PSG (in-lab polysomnogram), split-night study (in-lab PSG and pressure titration) or home sleep study (HST) within the previous 3 months.

Upon signing an informed consent, participants will be randomly assigned to start on either the KPAP (supplied by a SleepRes device) or the APAP (supplied by a ResMed device) arm when they arrive at the office. Each participant will then be given their new equipment and will be trained in proper use of the device assigned for the first treatment arm. The device will be used at home, nightly, for 4 weeks. Afterward, they will return to the office for their second visit. They will then be given the other device-along with the appropriate explanation on how to use it-that they will use on their second treatment arm. Subsequently, they will undergo a washout period of 1 week where no therapy will be used. Following the washout period, they will initiate another 4-week usage with the second therapy device. At the end of the second 4-week period, participants will return to the office for their third visit.

In both the APAP and KPAP arms, participants will have their therapy set to 5-20 cmH2O for one week. The pressure range will then be narrowed to ± 2 cmH2O around their 95% pressure level as assessed during the first week. This same pressure range will be used during the second arm for each patient.

During the KPAP arm, participants will be set to a double Comfort Setting drop according to the following scheme. This drop schedule will be implemented while the KPAP device is operating with automatic pressure adjustment.

Pset Drop 1 Drop 2 5.0 - 5.9 0 0 6.0 - 6.9 1 0 7.0 - 7.9 2 0 8.0 - 8.9 2 1 9.0 - 9.9 2 2 10.0 - 20.0 2 3

Phone calls to encourage use and assess adherence and side effects will be made at different time points during both treatment arms. Subjects using the device less than an average of 5 hours per night during the first week will be contacted on a more regular basis (weekly until 5 hour per night use is achieved) to address any problems and encourage use. If participants discontinue the use of the device during the home use period, they will still be encouraged to return for all testing per protocol. If a patient refuses to come in for further testing, they will be considered a lost to follow up and excluded from efficacy analysis.

  • 1 Day Phone Call (+2 days)
  • 7 Day Phone Call (+/- 3 days)
  • 14 Day Phone Call (+/- 3 days)
  • 21 Day Phone Call (+/- 3 days) to remind participants and schedule the office visit and device return on day 28
  • Equipment Return

After each arm, the patient will return to the office for the after-treatment visit (Visit 2 and Visit 3) to record the following:

  • Adverse Event Assessment
  • PROMIS Fatigue
  • Epworth Sleepiness Scale (ESS)
  • Functional Outcomes of Sleep Questionnaire (FOSQ)
  • Short Form 36 (SF36)
  • Comfort and Satisfaction, per Visual analog Scale (VAS)
  • Nightly adherence recording

Data collected from the therapy device will include the following:

  • Usage averaged over the 4-week period and nightly
  • Leak averaged over the 4-week period and nightly
  • P95 averaged over the 4-week period and nightly
  • Sleep events averaged over the 4-week period and nightly
03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. AHI > 10 on a previous PSG or HST (hypopneas requiring 4% desaturation).
  2. Central apneas \< 25% of events
  3. PLM (Periodic Limb Movements) arousal index \< 15

Exclusion criteria

Exclusion Criteria:

  1. A female of that is pregnant or intends to become pregnant.
  2. Any unstable or severe medical condition of any organ system including congestive heart failure, , renal failure, neuromuscular disease, etc., or at the discretion of the site Principal Investigator (PI).
  3. Taking medication that may affect sleep, sleepiness, or alertness including hypnotics, sedatives, alerting agents, stimulants, anticonvulsants, etc.
  4. The presence of any other sleep disorder (insomnia, periodic limb movement disorder, etc).
  5. Prior therapy or treatment for OSA.
  6. Chronic oxygen therapy.
  7. Excessive alcohol consumption (>14 drinks/week).
  8. The use of any illegal drug(s).
  9. Any condition that in the investigator's opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Placebo comparator
    4-weeks breathing on APAP

    Patients will breathe on APAP for 4 weeks simulating normal therapy. Usage, leak, P95/P90 and AHI will be recorded and averaged over the duration.

    Device: APAP

  • Experimental
    4-weeks breathing on KPAP

    Patients will breathe on TheraPAP for 4 weeks, which is the therapy under evaluation. Usage, leak, P95/P90 and AHI will also be recorded and averaged over the duration.

    Device: KPAP

Interventions

  • DeviceKPAP

    TheraPAP is a novel CPAP-based therapy in which pressure is dropped as much as 5 cmH2O starting at the beginning of inspiration and extending through the end of expiration where it rises back up to the true therapy pressure for a short period. It improves comfort by providing pressure only when it is needed and maintaining it at a low level the rest of the time. Normal CPAP/APAP therapy keeps pressure at the therapy level during the entire breath cycle, except with some alternate approaches where pressure is decreased but only during the expiratory phase.

  • DeviceAPAP

    Standard CPAP therapy where therapy pressure is automatically adjusted to prevent respiratory events from occurring. The TheraPAP prototype device will be used to operate in the APAP mode in addition to the TheraPAP intervention mode.

06

What researchers measure

Primary outcomes

  1. Usage

    Number of hours for which therapy is used per night

    Time frame: Averaged over every night for each 4-week arm

Secondary outcomes

  1. ESS Questionnaire

    Epworth Sleepiness Scale - a standard questionnaire to assess sleep quality. Scoring goes from 0 to 24 and higher scores means worsening sleepiness.

    Time frame: Filled out twice, once after completion of each 4-week arm (at week 4 and at week 9)

  2. FOSQ-10 Questionnaire

    Functional Outcomes of Sleep Questionnaire - 10 - a standard questionnaire to assess sleep quality. Scoring goes from 10 to 40 and higher scores means better functional outcome.

    Time frame: Filled out twice, once after completion of each 4-week arm (at week 4 and at week 9)

  3. Excess Leak or Leak

    Excess leak is patient circuit leak in excess of the normal leak required to prevent rebreathing in a CPAP device, which exits the circuit from the exhaust valve. Examples of excess leak include mask sealing leak or mouth opening. This excess leak will be averaged per night.

    Time frame: Averaged over every night for each 4-week arm

  4. P95/P90

    Standard CPAP measurement - pressure levels that eliminate breathing obstructions for at least 90% to 95% of the sleep period

    Time frame: Averaged over every night for each 4-week arm

  5. AHI

    Apnea/Hypopnea Index - measure of the number of obstructive breathing events per hour experienced by the patient

    Time frame: Averaged over every night for each 4-week arm

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Dec 2027, 10 months later.

Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 10 months is below that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Jul 2026 → Feb 2027, primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2024
First posted
May 14, 2024
StartEst.
Feb 1, 2027was Jul 2026
Primary completionEst.
Dec 1, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2026→Feb 1, 2027
Nov 19, 2026
Primary completion
Dec 1, 2026→Dec 1, 2027
Nov 19, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Jul 1, 2026→Feb 1, 2027
    Primary completion Dec 1, 2026→Dec 1, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 2 other changes: verification date and documents

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06413134
Lead sponsor
SleepRes Inc.
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Feb 1, 2027 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Philip Tallent, MD
Contact
gtallent@sleepcenterinfo.com
615-893-4896
Bernard Hete, PhD
Contact
bhete@sleepres.com
412-398-2846
William H Noah, MD
study director · SleepRes, LLC., Sleep Centers of Middle Tennessee, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion